AMRI : Summary for Albany Molecular Research, Inc. - Yahoo Finance

U.S. Markets closed

Albany Molecular Research, Inc. (AMRI)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.39-2.22 (-11.93%)
At close: 4:00PM EST

16.40 0.01 (0.06%)
After hours: 4:43PM EST

People also watch
ARQLARRYALKSENZNANIK
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close18.61
Open16.95
Bid6.76 x 1000
Ask16.78 x 7000
Day's Range15.60 - 17.58
52 Week Range12.45 - 19.35
Volume1,435,944
Avg. Volume218,352
Market Cap681.51M
Beta1.36
PE Ratio (TTM)-11.22
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press9 hours ago

    Albany Molecular Research posts 4Q loss

    Albany Molecular Research Inc. on Tuesday reported a fourth-quarter loss of $15.4 million, after reporting a profit in the same period a year earlier. On a per-share basis, the Albany, New York-based company ...

  • PR Newswire10 hours ago

    AMRI Announces Agreement with Accord Healthcare to Jointly Develop, Manufacture and Commercialize Parenteral Drug Products

    ALBANY, N.Y., Feb. 21, 2017 /PRNewswire/ -- AMRI (AMRI) today announced that it has entered into an agreement with the pharmaceutical group Ferrer  and Accord Healthcare, Inc. ("Accord Healthcare") to jointly develop and manufacture an undisclosed complex parenteral drug product for registration and subsequent commercialization in the United States with the option to partner on additional drug products. Under terms of the agreement, AMRI will work with Ferrer to develop and initially provide cGMP manufacturing and analytical support for the registration of the new product. Accord Healthcare will be responsible for advancing the product candidate through regulatory submission and commercialization.

  • PR Newswire10 hours ago

    AMRI Announces Fourth Quarter and Full Year 2016 Results and Provides 2017 Outlook

    ALBANY, N.Y., Feb. 21, 2017 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today reported financial and operating results for the fourth quarter and full year ended December 31, 2016 and provided an outlook for 2017. ...